Company
Headquarters: Taichung, Taiwan
Employees: 94
TW$14.52 Billion
TWD as of Jan. 1, 2025
US$442.4 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $113.24 B |
CSL Limited | $95.75 B |
Regeneron Pharmaceuticals, Inc. | $76.33 B |
Marinomed Biotech AG | $56.13 B |
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
Ever Supreme Bio Technology Co., Ltd engages in the research and development of cell gene therapies based on immune cells and stem cells. Its products in development include UMSC01, a drug candidate in Phase 2 clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase 3 clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product in Phase 1 clinical trials for use in the treatment of triple-negative breast cancer; and gene modified mesenchymal stem cells and fucoidan nanoparticles for use in the treatment of malignant tumor. The company was founded in 2016 and is based in Taichung, Taiwan.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Ever Supreme Bio Technology Co. Ltd has the following listings and related stock indices.
Stock: TWSE: 6712 wb_incandescent